Protective effect of angelica sinensis polysaccharide on experimental immunological colon injury in rats

World Journal of Gastroenterology

Volumn 9, Issue 12, 2003, Pages 2786-2790

  Liu, Shao Ping ^a   Dong, Wei Guo ^a   Wu, Dong Fang ^a   Luo, He Sheng ^a   Yu, Jie Ping ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANGELICA SINENSIS EXTRACT; ANGELICAE SINENSIS EXTRACT; ENEMA; EPIDERMAL GROWTH FACTOR; HERBACEOUS AGENT; INTERLEUKIN 10; INTERLEUKIN 2; MALONALDEHYDE; MESALAZINE; MYELOPEROXIDASE; NITRIC OXIDE; PEROXIDASE; POLYSACCHARIDE; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANGELICA SINENSIS; ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD; CHEMISTRY; COLITIS; COLON DISEASE; COLON INJURY; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; IATROGENIC DISEASE; IMMUNOCHEMISTRY; IMMUNOLOGY; IMMUNOMODULATION; IMMUNORADIOMETRIC ASSAY; INJURY; MALE; NONHUMAN; OCCULT BLOOD TEST; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYTOTHERAPY; PROTECTION; PROTEIN EXPRESSION; RAT; RAT STRAIN; TISSUE LEVEL; UPREGULATION; WOUND HEALING;

EID: 0346337051     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i12.2786     Document Type: Article

References (48)

1. Xie L, Yang LH, Li XH. Research on the pharmacologic effects of Angelica Sinensis. Zhongyiyao Yanjiu 2000; 16: 56-58
2. Ling XM, Ding H, Luo SD, Zhang XJ, Zhang LH. Study on the pharmacological mechanism of angelica polysaccharide on the immunocompetence and the effects of its anti-oxidation. Zhongguo Yiyuan Yaoxue Zazhi 2002; 22: 584-586
3. Ye YN, Liu ES, Li Y, So HL, Cho CC, Sheng HP, Le SS, Cho CH. Protective effect of polysaccharides-enriched fraction from Angelica sinensis on hepatic injury. Life Sci 2001; 69: 637-646
4. Ding H, Peng R, Yu J. Modulation of angelica sinensis polysaccharides on the expression of nitric oxide synthase and Bax, Bcl-2 in liver of immunological liver-injured mice. Zhonghua Ganzangbing Zazhi 2001; 9(Suppl): 50-52
5. Yang TH, Lu BH, Jia SM, Mei QB. Immunoregulation effect of Angelica polysaccharide isolated from Angelica sinensis on mice. Zhongguo Yaolixue Tongbao 2003; 19: 448-451
6. Xia XY, Peng RX, Wang ZY. The effect of angelica sinensis polysaccharide and its ingredients on mice's immunocompetence. Wuhan Daxue Xuebao (Medicine Edition) 2001; 22: 199-201
7. Cho CH, Mei QB, Shang P, Lee SS, So HL, Guo X, Li Y. Study of the gastrointestinal protective effects of polysaccharides from Angelica sinensis in rats. Plant Med 2000; 66: 348-351
8. Ye YN, Koo MW, Li Y, Matsui H, Cho CH. Angelica sinensis modulates migration and proliferation of gastric epithelial cells. Life Sci 2001; 68: 961-968
9. Ye YN, So HL, Liu ES, Shin VY, Cho CH. Effect of polysaccharides from Angelica sinensis on gastric ulcer healing. Life Sci 2003; 72: 925-932
10. Xia B. Etiology and pathogenesis of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2001; 9: 245-250
11. Kirsner JB. Historical origins of current IBD concepts. World J Gastroenterol 2001; 7: 175-184
12. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000; 51: 289-298
13. Xia B, Guo HJ, Crusius JBA, Deng CS, Meuwissen SGM, Pena A. In vitro production of TNF-alpha, IL-6 and sIL-2R in Chinese patients with ulcerative colitis. World J Gastroenterol 1998; 4: 252-255
14. Indaram AVK, Nandi S, Weissman S, Lann S, Bailey B, Blumstein M, Greenberg R, Bank S. Elevated basal intestinal mucosal cytokine levels in asymptomatic first-degree relatives of patients with Crohn's disease. World J Gastroenterol 2000; 6: 49-52
15. Momeleone G, Macdonald TT. Manipulation of cytokines in the management of patients with inflammatory bowel disease. Ann Med 2000; 32: 552-560
16. Blam ME, Stein RB, Lichtenstein GR. Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: Current and future perspectives. Am J Gastroenterol 2001; 96: 1977-1997
17. Das KM, Farag SA. Current medical therapy of inflammatory bowel disease. World J Gastroenterol 2000; 6: 483-489
18. Fiocchi C. TGF-beta/Smad signaling defects in inflammatory bowel disease: Mechanisms and possible novel therapies for chronic inflammation. J Clin Invest 2001; 108: 523-526
19. Mei Q, Yu JP, Xu JM, Wei W, Xiang L, Yue L. Melatonin reduces colon immunological injury in rats by regulating activity of macrophages. Acta Pharmacol Sin 2002; 23: 882-886
20. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989; 96: 795-803
21. Zhang JT. Modern Experimental Methods in Pharmacology. 1st ed. Beijing: Beijing Medical College Xiehe Medical College Pub 1997: 726-762
22. Pavlick KP, Laroux FS, Fuseler J, Wolf RE, Gray L, Hoffman J, Grisham MB. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med 2002; 33: 311-322
23. Krieglstein CF, Cerwinka WH, Laroux FS, Salter JW, Russell JM, Schuermann G, Grisham MB, Ross CR, Granger DN. Regulation of murine intestinal inflammation by reactive metabolites of oxygen and nitrogen: Divergent roles of superoxide and nitric oxide. J Exp Med 2001; 194: 1207-1218
24. Huang J, Luo HS, Yang JX. Therapeutic effects of butyrate on nitric oxide abnormality in experimental ulcerative colitis in rats. Shijie Huaren Xiaohua Zazhi 2001; 9: 967-969
25. Bai AP, Shen ZX, Yu BP, Luo Y. Nitric oxide and the acute injury in colitis model. Shijie Huaren Xiaohua Zazhi 1999; 7: 900-901
26. Li JH, Yu JP, He XF, Xu XM. Expression of NF-κB in rats with TNBS-induced ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2003; 11: 214-218
27. Brown GD, Taylor PR, Reid DM, Willment JA, Williams DL, Martinez-Pomares L, Wong SY, Gordon S. Dectin-1 is a major beta-glucan receptor on macrophages. J Exp Med 2002; 196: 407-412
28. Linehan SA, Martinez-Pomares L, da Silva RP, Gordon S. Endogenous ligands of carbohydrate recognition domains of the mannose receptor in murine macrophages, endothelial cells and secretory cells; Potential relevance to inflammation and immunity. Eur J Immunol 2001; 31: 1857-1866
29. Romagnani S. Th1/Th2 cells. Inflamma Bowel Dis 1999; 5: 285-294
30. Van Damme N, De Keyser F, Demetter P, Baeten D, Mielants H, Verbruggen G, Cuvelier C, Veys EM, De Vos M. The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome. Clin Exp Immunol 2001; 125: 383-390
31. Bemiss CJ, Mahon BD, Henry A, Weaver V, Cantorna MT. Interleukin-2 is one of the targets in 1,25-dihydroxyvitamin D3 in the immune system. Arch Biochem Biophys 2002; 402: 249-254
32. Dejaco C, Reinisch W, Lichtenberger C, Waldhoer T, Kuhn I, Tilg H, Gasche C. In vivo effects of recombinant human interleukin-10 on lymphocyte phenotypes and leukocyte activation markers in inflammatory bowel disease. J Investig Med 2000; 48: 449-456
33. Asseman C, Mauze S, Leach MW, Coffmann RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999; 190: 995-1004
34. 1-mediated suppression of T helper cell type 1 response occous by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation. J Exp Med 2000; 192: 41-52
35. Hahm KB, Im YH, Parks TW, Park SH, Markowitz S, Jung HY, Green J, Kim SJ. Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut 2001; 49: 190-198
36. Wiercinska-Drapalo A, Flisiak R, Prokopowicz D. The role of transforming growth factors beta in pathogenesis of ulcerative colitis. Pol Merkuriusz Lek 2001; 10: 177-179
37. Fu XB, Yang YH, Sun TZ, Gu XM, Jiang LX, Sun XQ, Sheng ZY. Effect of intestinal ischemia-reperfusion on expressions of endogenous basic fibroblast growth factor and transforming growth factor β in lung and its relation with lung repair. World J Gastroenterol 2000; 6: 353-355
38. Yuan YZ, Lou KX, Gong ZH, Tu SP, Zhai ZK, Xu JY. Effects and mechanisms of emodin on pancreatic tissue EGF expression in acute pancreatitis in rats. Shijie Huaren Xiaohua Zazhi 2001; 9: 128-130
39. Xia L, Yuan YZ, Xu CD, Zhang YP, Qiao MM, Xu JX. Effects of epidermal growth factor on the growth of human gastric cancer cell and the implanted tumor of nude mice. World J Gastroenterol 2002; 8: 455-458
40. Wu BW, Wu Y, Wang JL, Lin JS, Yuan SY, Li A, Cui WR. Study on the mechanism of epidermal growth factor-induced proliferation of hepatoma cells. World J Gastroenterol 2003; 9: 271-275
41. Beck PL, Podolsky DK. Growth factors in inflammatory bowel disease. Inflamm Bowel Dis 1999; 5: 44-60
42. Higasshiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991; 251: 936-939
43. Chen DL, Wang WZ, Wang JY. Epidermal growth factor prevents gut atrophy and maintains intestinal integrity in rats with acute pancreatitis. World J Gastroenterol 2000; 6: 762-765
44. Banan A, Zhang Y, Losurdo J, Keshavarzian A. Carbonylation and disassembly of the F-actin cytoskeleton in oxidant induced barrier dysfunction and its prevention by epidermal growth factor and transforming growth factor alpha in a human colonic cell line. Gut 2000; 46: 830-837
45. Banan A, Fields JZ, Talmage DA, Zhang L, Keshavarzian A. PKC-zeta is required in EGF protection of microtubules and intestinal barrier integrity against oxidant injury. Am J Physiol Gastrointest Liver Physiol 2002; 282: G794-808
46. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002; 122: 1592-1608
47. Miller MD, Krangel MS. Biology and biochemistry of the chemokines: A family of chemotactic and inflammatory cytokines. Crit Rev Immunol 1992; 12: 7-46
48. Li Y, Wang HY, Cho CH. Association of heparin with basic fibroblast growth factor, epidermal growth factor, and constitutive nitric oxide synthase on healing of gastric ulcer in rats. The J Pharmacol Exp Ther 1999; 290: 789-796